A Study to Evaluate INCA036873 in Participants With Advanced Solid Tumors and Hematological Malignancies
Trial statusRecruiting
Trial phasePhase 1
Trial typeInterventional
Biological sexAll
Age18+
SponsorIncyte Corporation
About this trial
A study to evaluate the safety and tolerability of INCA036873 in participants with advanced solid tumors and hematological malignancies.
Eligibility criteria
Qualifiers
Age ≥18 years.
ECOG performance status of 0 or 1.
Clear cell renal cell carcinoma (ccRCC).
Diffuse large B-cell lymphoma (DLBCL, NOS).
Disqualifiers
Untreated or progressive CNS disease unless previously treated and stable.
Other active invasive malignancy within 2 years (except certain low-risk cancers).
Prior CD70-targeting therapy, including CAR T.
ASCT or CAR T ≤12 weeks before enrollment; prior organ or allogeneic transplant.
Trial design
Treatments tested in this trial
- INCA036873
Treatment groups
280 Participants
are divided into 3 treatment groupsLocations
22Australia
Macquarie University Hospital02109, SydneyNew South Wales, Australia
Princess Alexandra Hospital Australia04102, WoolloongabbaQueensland, Australia
Cancer Research Sa05000, AdelaideSouth Australia, Australia
Peter Maccallum Cancer Centre-Royal Melbourne Hospital03000, MelbourneVictoria, Australia
Sponsors and collaborators
Incyte Corporation
Lead sponsor
Source ClinicalTrials.gov